Raltitrexed
- Generic Name
- Raltitrexed
- Brand Names
- Tomudex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N4O6S
- CAS Number
- 112887-68-0
- Unique Ingredient Identifier
- FCB9EGG971
- Background
Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
- Indication
For the treatment of malignant neoplasm of colon and rectum
- Associated Conditions
- Advanced Colorectal Cancer, Pleural Mesotheliomas
- Associated Therapies
- -
CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 124
- Registration Number
- NCT06652412
Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC
- Conditions
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT06427005
- Locations
- 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 93
- Registration Number
- NCT05628038
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 39
- Registration Number
- NCT05435313
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 50
- Registration Number
- NCT05426811
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-06-08
- Target Recruit Count
- 90
- Registration Number
- NCT05160896
- Locations
- 🇨🇳
the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
Raltitrexed in HIPEC
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 15
- Registration Number
- NCT04761185
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04241731
- Locations
- 🇨🇳
Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT03823079
RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03813641
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.